Chardan Capital analyst Keay Nakae maintained a Sell rating on Mesoblast (NASDAQ:MESO) Ltd on Friday, setting a price target of $7.5, which is approximately 44.73% below the present share price of $13.57.
Nakae expects Mesoblast Ltd to post earnings per share (EPS) of $0.00 for the fourth quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Mesoblast, with an average price target of $14.7.
The analysts price targets range from a high of $20 to a low of $7.5.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $1.31 million and a net profit of -$35.56 million. The company's market cap is $1.99 billion.
According to TipRanks.com, Chardan Capital analyst Keay Nakae is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 12.4% and a 46.67% success rate.
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.